ProCE Banner Activity

An Expert Focus on Cultural Considerations for Managing MASH

Clinical Thought

Learn how the treatment of metabolic dysfunction‒associated steatohepatitis should be tailored to meet the individual patient’s needs, including cultural considerations regarding dietary modifications and participation in clinical trials.

Released: February 19, 2024

Share

Faculty

Mazen Noureddin

Mazen Noureddin, MD, MHSc

Professor of Medicine
Houston Methodist Hospital
Director 
Houston Research Institute
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC, in partnership with the American Gastroenterological Association (AGA) and Practicing Clinicians Exchange (PCE).

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

AGA

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Mazen Noureddin, MD, MHSc

Professor of Medicine
Houston Methodist Hospital
Director 
Houston Research Institute
Houston, Texas

Mazen Noureddin, MD, MHSc: consultant/advisor/speaker: 89Bio, Altimmune, BI, Corecept, Cytodyn, GlaxoSmithKline, Madrigal, Merck, Northsea, Novo Nordisk, Takeda, Terns; researcher: Akero, Allergan, BI, Bristol-Myers Squibb, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, GlaxoSmithKline, Madrigal, Novartis, Novo Nordisk,  Shire, Takeda, Terns, Viking and Zydus; individual publicly traded stock/stock options: ChronWell, CIMA, Cytodyn, Rivus Pharma.